Abstract: Forms I and II of the mesylate salt of the compound of formula (I), a preparation methods thereof, a pharmaceutical composition containing the crystal forms, and the use of the crystal forms in treating diseases mediated by activating and resistance mutations of EGFR, in particular cancer, in mammal, in particular in human.
Type:
Grant
Filed:
March 1, 2017
Date of Patent:
February 4, 2020
Assignee:
SHANGHAI ALLIST PHARMACEUTICAL AND MEDICAL TECH CO
Abstract: A mesylate salt of the compound of formula (I), the preparation method thereof, a pharmaceutical composition containing said salt and the use of said salt in treating diseases mediated by activating and resistance mutations of EGFR, in particular cancers, in mammal, in particular human. The mesylate salt of the compound of formula (I) has a high bioavailability in animal, and can remarkably inhibit the growth of transplanted tumors in animal and show a good safety.
Type:
Grant
Filed:
March 1, 2017
Date of Patent:
November 12, 2019
Assignee:
SHANGHAI ALLIST PHARMACEUTICAL AND MEDICAL TECH CO